Genesis Healthcare (GEN) Stock Price, News & Analysis

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genesis Healthcare in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GEN shares.
View GEN analyst ratings or view top-rated stocks.

5 Wall Street analysts have issued 1 year price objectives for Genesis Healthcare's stock. Their GEN share price targets range from $25.00 to $28.00. On average, they anticipate the company's stock price to reach $26.00 in the next year. This suggests a possible upside of 26.8% from the stock's current price.
View analysts price targets for GEN or view top-rated stocks among Wall Street analysts.

Genesis Healthcare, Inc. (NYSE:GEN) issued its quarterly earnings data on Thursday, February, 1st. The company reported $0.45 EPS for the quarter, hitting analysts' consensus estimates of $0.45. The company had revenue of $953 million for the quarter, compared to the consensus estimate of $955.80 million. Genesis Healthcare had a trailing twelve-month return on equity of 155.48% and a net margin of 17.83%.

Genesis Healthcare announced a quarterly dividend on Thursday, February 1st. Shareholders of record on Monday, February 19th will be paid a dividend of $0.125 per share on Wednesday, March 13th. This represents a $0.50 annualized dividend and a yield of 2.44%. The ex-dividend date of this dividend is Thursday, February 15th.
Read our dividend analysis for GEN.

Genesis Healthcare (NYSE:GEN) pays an annual dividend of $0.50 per share and currently has a dividend yield of 3.05%. The dividend payout ratio is 55.56%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, GEN will have a dividend payout ratio of 29.07% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for GEN.

ETFs with the largest weight of Genesis Healthcare (NYSE:GEN) stock in their portfolio include Amplify Cybersecurity ETF (HACK), Global X Cybersecurity ETF (BUG), First Trust Nasdaq Cybersecurity ETF (CIBR), ASYMshares ASYMmetric S&P 500 ETF (ASPY), First Trust S&P 500 Diversified Dividend Aristocrats ETF (RNDV), VictoryShares Nasdaq Next 50 ETF (QQQN), Invesco S&P 500 Equal Weight Technology ETF (RYT) and Invesco S&P 500 Equal Weight Technology ETF (RSPT).

Genesis Healthcare updated its fourth quarter 2024 earnings guidance on Thursday, February, 1st. The company provided earnings per share guidance of 0.520-0.540 for the period, compared to the consensus earnings per share estimate of 0.530. The company issued revenue guidance of $960.0 million-$970.0 million, compared to the consensus revenue estimate of $974.4 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Genesis Healthcare investors own include Flaherty & Crumrine Preferred Securities Income Fund (FFC), Vaxart (VXRT), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), AT&T (T), Amarin (AMRN), Government Properties Income Trust (GOV), Advanced Micro Devices (AMD), Bausch Health Companies (BHC) and

Genesis Healthcare's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (0.25%), Los Angeles Capital Management LLC (0.23%), Allspring Global Investments Holdings LLC (0.05%), Diversified Trust Co (0.03%), State of Michigan Retirement System (0.03%) and Alaska Permanent Fund Corp (0.02%). Insiders that own company stock include Natalie Marie Derse and Ondrej Vlcek.
View institutional ownership trends.